AndroGel defendants try to bar FTC studies from trial; Hamburg to serve as IOM adviser;

@FiercePharma: AZ's Onglyza has most to lose at FDA safety confab, analysts say. Story | Follow @FiercePharma

@EricPFierce: Supply chain slip results in expired #Pfizer birth control pills being sold in Canada. More | Follow @EricPFierce

@CarlyHFierce: Mid-cap biotech beats most of the big dogs with 21.9% revenue growth. Article | Follow @CarlyHFierce

> AbbVie ($ABBV) and its fellow defendants asked a judge to bar the Federal Trade Commission from using studies about the pharmaceutical industry in an upcoming pay-for-delay trial over AndroGel. Report (reg. req.)

> Former FDA Commissioner Margaret Hamburg has joined the Institute of Medicine as a senior adviser focused on international matters. Report

> A Georgia federal judge ordered prosecutors to add details to an indictment accusing an accountant of insider trading related to a $1.9 billion Sanofi ($SNY) acquisition. Report (reg. req.)

> Pharmacy chain Walgreens Boots Alliance ($WBA) expanded its restructuring program with plans to close 200 U.S. stores. Report (sub. req.)

> Four Indian pharma companies saw their shares fall after Bank of America Merrill Lynch issued a downgrade. Report

Medical Device News

@FierceMedDev: France's Labco tiptoes closer to IPO. FierceDiagnostics article | Follow @FierceMedDev

@VarunSaxena2: ICYMI from FierceDiagnostics: Alere earns FDA clearance for rapid diagnostic of Strep A. News | Follow @VarunSaxena2

@EmilyWFierce: Roche nabs EU approval for Avastin for cervical cancer. Report from FiercePharma | Follow @EmilyWFierce

> Aethlon Medical eyes full marketing approval for Ebola biofiltration device. Story

> Synaptive's 'GPS for the brain' gets FDA green light. Article

Biotech News

@FierceBiotech: One of Shire's top blockbuster drug prospects flops in a key PhII study. News | Follow @FierceBiotech

@JohnCFierce: What bubble? Woodford boosts biotech fund max to $1.2B as investors crowd in. More | Follow @JohnCFierce

@DamianFierce: ICYMI: The thrilling conclusion to #FierceMadness and why I've had "One Shining Moment" stuck in my head all day. Story | Follow @DamianFierce

> Edge Therapeutics hauls in $72.5M for brain injury R&D. More

> Prothena files for follow-on offering to build $400M R&D war chest. News

CRO News

> WuXi gets a manufacturing subsidiary on the Chinese stock market. Report

> Parexel partners up for clinical trial education. News

> Catalent reaches into Australia with latest buyout. More

> PPD sets off in Japan with SNBL joint venture. Story

> AMRI shutters another plant with an eye on its bottom line. Article

Vaccines News

> GSK relocates vaccine R&D to Maryland with new global center. Story

> Sanofi teams up with VBI Vaccines to improve vaccine stability. News

> Duke University scores $20M from NIH to develop HIV vaccine. Report

> Sanofi 'flipping the model' for high-stakes dengue rollout. More

> Northwest Bio gets $40M more for controversial brain cancer vaccine. Article

Pharma Manufacturing News

> Report: Supply chain efficiency can boost both top- and bottom-line results. Story

> Cipla buying Brazilian distributor for beachhead there. News

> Expired Pfizer contraceptives recalled after supply chain fumble. Report

> Indonesia market expanding but local producers can't keep up. Article

> Chinese drugmaker to build $60M API plant. Story

Pharma Asia News

> Japan, S. Korea hospitals ink clinical pact on regenerative medicine. News

> China's Sihuan marks first U.S. patient enrollment of PhI oncology candidate. Item

> India drug price chief sacked as essential drug prices rise. Article

> U.S. unit of Glenmark settles Medicaid charges for $25M. Story

> Asian device market set to leap to $15B in 2017. Report

And Finally... After a measles outbreak in California, state lawmakers have advanced a bill eliminating parental waivers exempting kids from vaccination. Report (sub. req.)

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.